Market Cap • Atrium Therapeutics
RNA
Atrium Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering the development of atrial-selective gene therapies for the treatment of atrial fibrillation (AFib), the most prevalent sustained cardiac arrhythmia worldwide. The company's mission is to provide a durable, one-time treatment that restores and maintains normal sinus rhythm, addressing the limitations of current standard-of-care treatments such as anti-arrhythmic drugs and catheter ablation. Atrium's proprietary platform focuses on localized delivery of genetic material to the heart's atria. Its lead product candidate, ATR-101, is an investigational gene therapy designed to be delivered via a single administration to the epicardial surface of the atria during a minimally invasive procedure or concomitant with cardiac surgery. ATR-101 works by expressing a modified potassium channel that prolongs the atrial refractory period, thereby suppressing the electrical triggers and substrates that sustain AFib. By targeting the underlying electrophysiological mechanisms of the disease specifically within the atrial tissue, Atrium Therapeutics aims to minimize systemic side effects and improve long-term outcomes for patients suffering from paroxysmal or persistent AFib. The company is positioned at the intersection of cardiovascular medicine and advanced genetic therapeutics, seeking to fill a significant unmet need in the management of chronic heart rhythm disorders.
10,9B
Market Cap
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
9,3B
EV
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
493,7
EV/Revenue
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
-12,5
EV/EBITDA
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
-12,4
EV/EBIT
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!